58B1

58B1 is a monoclonal antibody clone that targets the immune checkpoint molecule B7-H3 (CD276). B7-H3 is an immunomodulatory protein frequently overexpressed in various malignancies, including acute myeloid leukemia (AML) and solid tumors, where it contributes to immune evasion. 58B1 was identified and characterized in research conducted at the University of Texas MD Anderson Cancer Center and the University of Tübingen. The antibody functions by blocking the immunomodulatory activity of B7-H3, thereby enhancing the cytotoxicity of natural killer (NK) cells against malignant cells. In preclinical studies, 58B1 demonstrated the ability to increase NK cell-mediated apoptosis in AML cell lines and inhibit leukemia growth in patient-derived xenograft (PDX) models, although it was evaluated alongside other clones such as T-1A5 and HEK5-1B3.